On March 4, Sesen Bio's (SESN) President and CEO Dr. Thomas Cannell held a conference call, primarily to update the status and progress of Vicinium.
A Brief Background
Vicinium is being developed for non-muscle invasive bladder cancer (NMIBC), a very common cancer for which no new treatment has been approved in 20+ years and represents an urgent unmet need. While Bacillus Calmette-Guerin ((BCG)) is approved for treatment of NMIBC, it will eventually fail most patients. Complete removal of the bladder is recommended once BCG is no longer effective. Valstar (Valrubicin), the third line